

**NOV
10**

INTERNATIONAL LUNG CANCER SUMMIT

CLICK HERE TO SAVE THE DATE

Dear Friends and Colleagues,

Following the great success of the International Lung Cancer Summit (ILCS) last year with over 1200 participants, we are delighted to invite you on behalf of the organising committee to the 5th edition of this interactive hybrid meeting on 10 November 2023. Similar to recent years, the ILCS will showcase latest discoveries and advances performed towards the treatment of lung cancer. The conference will again leverage digital channels to provide with an exceptional outreach and opportunity for delegates from Medical Offices, Universities, and Institutes to interact with world-class Medical Oncologists and Industry Professionals working in the field of lung cancer treatment and research.

The ILCS constitutes an ideal platform to share knowledge and seamless treatment procedures with our local and international speakers from USA, Spain, Italy, Germany, Austria, UK, Netherlands, and Switzerland. We kindly ask you to make a note of the conference and hope to see numerous appearances – your generous support is much appreciated!

We look forward to meeting you soon either virtually or on site in Lausanne!



Alfredo Addeo, MD
Conference Chair



Solange Peters, MD-PhD
Conference Chair



HUG

Hôpitaux
Universitaires
Genève

OncoViews

PEAK
medicals

TENTATIVE AGENDA

10.00	Welcome & Introduction	S. Peters & A. Addeo	Switzerland
10.02	What tests are must-haves in lung cancer diagnostics today, and what's next for tomorrow	Anne Schultheis	Germany
10.30	Current standards and future perspectives in targeting EGFR and ALK	Zofia Piotrowska	USA
10.50	Rare But Actionable: available therapies for RET, METex14 and NTRK	Maximilian Hochmair	Austria
11.15	BREAK		
11.40	KRAS, HER2 and the emergence of more actionable mutations	Tina Cascone	USA
12.05	SCLC: New treatment paradigms and a glimpse into our treatment options of tomorrow	Kaushal Parikh	USA
12.30	SATELLITE INDUSTRY SYMPOSIA		
14.00	Latest advances in thoracic surgery for NSCLC	Jean Y. Perentes	Switzerland
14.30	DEBATE: Neo-Adjuvant vs. Adjuvant IO in early NSCLC (PRO vs. CON, exact titles and sides to be determined)	Thomas Newsom-Davis Antonio Passaro	UK Italy
15.00	BREAK		
15.20	IO in NSCLC: are there differences between the PD-(L)1 inhibitors?	Rosario García Campelo	Spain
15.50	Beyond PD-1 and CTLA-4 inhibition: Where is IO headed in non-oncogenic NSCLC	Lizza Hendriks	Netherlands
16.15	Panel Discussion: Open Questions, Patient Cases & Guidelines	All Speakers & Attendees	
16.30	Closing Remarks	S. Peters & A. Addeo	Switzerland

THIS CONFERENCE IS INTERNATIONALLY ACCREDITED AND ENDORSED BY



European Accreditation Council
for Continuing Medical Education
(EACCME)
An Institution of the UEMS




INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

MEET OUR AUDIENCE


1272 PARTICIPANTS FROM 76 COUNTRIES



NUMBER OF PARTICIPANTS BY PROFESSION




DISTRIBUTION OF PARTICIPATION PREFERENCE BY PROFESSION




Numbers include live attendees (on October 7) and on-demand viewers (from October 8 to October 31)

Status: 31 October 2022

TOP 30 COUNTRIES BY NUMBER OF HCPS ONLY



HOW LIKELY ARE YOU TO ATTEND THE LUNG CANCER SUMMIT AGAIN?



Numbers include live attendees (on October 7) + on-demand viewers (from October 8 - 31), specific countries upon request

Status: 31 October 2022

WHAT PEOPLE SAY ABOUT THE ILCS



Certainly my preferred lung meeting of the year. And the ILCS is by far the best virtual one I've seen so far.



Probably one of the best 1 day conferences I have attended, not only engaging on the online platform but I was able to engage through Twitter, which many of the speakers use and this made me feel included in the discussions.